Mechanisms of Action of Silymarin for Hepatitis C
Mechanisms of Action of Silymarin for Hepatitis C
批准号:
7384347
负责人:
STEPHEN J. POLYAK
金额:
$24.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2010-03-31
关键词:
Adverse effectsAffectAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsAntiviral AgentsArtsBotanicalsCaringCellsChronicChronic Hepatitis CClinical TreatmentClinical TrialsComplementary and alternative medicineDataDiseaseDoseFosteringFoundationsFractionationFutureGenetic TranscriptionGenotypeGrantGray unit of radiation doseHealthHepatitis CHepatitis C virusHepatocyteHumanIndustryInfectious hepatitidesInflammatoryInflammatory ResponseInterferonsLeadLiverLiver diseasesMilk ThistleMolecularOxidation-ReductionOxidative StressPathway interactionsPatientsPlant PreparationsPlantsPreparationProteinsReportingResearchResearch DesignReverse Transcriptase Polymerase Chain ReactionRibavirinSignal PathwaySignal TransductionSignal Transduction PathwaySilymarinSolidSourceStandardizationStandards of Weights and MeasuresSystemTherapeuticThinkingTimeTreatment ProtocolsViralVirusWestern Blottinganti-hepatitis Cbasechemokinecytokineimprovedinterferon therapynovelpre-clinical researchprogramsprophylacticresponsesuccesstranscription factorviral RNAvirus culture
中文摘要
描述(申请人提供):丙型肝炎病毒(丙型肝炎病毒)是一种全球性的肝脏疾病,影响超过1.7亿人。唯一被批准的慢性丙型肝炎治疗方法是干扰素和利巴韦林,这只能治愈大约50%的感染患者。考虑到干扰素治疗的成功机会和明显的副作用,许多患者服用水飞蓟等植物药物。水飞蓟中的有效成分是水飞蓟素(SM),它被认为可以促进肝脏健康。然而,SM是如何促进肝脏健康的还不清楚。此外,植物业缺乏对来源植物的适当标准化和植物提取物的制备。我们建议使用一种经过仔细标准化和验证的SM制剂来确定SM如何促进健康的肝脏。我们假设丹参作为一种抗炎和抗病毒药物来保护肝脏免受丙型肝炎病毒感染。我们相信,这些研究将为SM未来在慢性丙型肝炎患者中的临床试验提供坚实的基础。项目简介:慢性丙型肝炎是一种全球性的肝脏疾病,影响超过1.7亿人。它由丙型肝炎病毒(丙型肝炎病毒)引起。感染者的治疗选择有限、昂贵、与主要副作用相关,而且往往疗效有限。本项目将研究植物水飞蓟素的保肝作用机制,为替代和补充药物治疗慢性丙型肝炎提供合理的依据。
英文摘要
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a global disease of the liver that affects over 170 million people. The only approved treatment for chronic hepatitis C is interferon (IFN) and ribavirin, which only cures about 50% of infected patients. Given the chance of success and significant side effects associated with IFN therapy, many patients consume botanicals such as milk thistle. The active ingredient in milk thistle is Silymarin (SM), which is thought to promote a healthy liver. However, exactly how SM promotes a healthy liver is not known. Furthermore, the botanical industry lacks proper standardization of the source plants and preparation of botanical extracts. We propose to determine how SM promotes a healthy liver, using a carefully standardized and validated preparation of SM. We hypothesize that SM acts as an anti-inflammatory and anti-viral agent to protect the liver from HCV infection. We believe these studies will provide a solid foundation for future clinical trials of SM in patients with chronic hepatitis C. Project Narrative: Chronic hepatitis C is a global disease of the liver that affects over 170 million people. It is caused by a hepatitis C virus (HCV). Treatment options for infected people are limited, expensive, associated with major side effects, and frequently of limited efficacy. This project will investigate the mechanisms of hepatoprotection of the botanical silymarin to provide a rational basis for alternative and complementary medicine approaches to treatment of chronic hepatitis C.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an Oral Pan-Coronavirus Drug Cocktail
-
批准号:10714472
-
项目类别:
-
资助金额:$70.24万
-
财政年份:2023
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Persistence of HCV-Induced Perturbations of Cellular Pathways Post DAA Cure in Advanced Liver Disease
-
批准号:10118278
-
项目类别:
-
资助金额:$47.85万
-
财政年份:2020
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Mechanisms of Silymarin Hepatoprotection
-
批准号:8707387
-
项目类别:
-
资助金额:$43.86万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Mechanisms of Silymarin Hepatoprotection
-
批准号:8514925
-
项目类别:
-
资助金额:$43.86万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
HCV-Host Interactions During Antiviral Therapy
-
批准号:8292304
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Mechanisms of Silymarin Hepatoprotection
-
批准号:8195766
-
项目类别:
-
资助金额:$47.03万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
HCV Symposium 2011
-
批准号:8128005
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Mechanisms of Silymarin Hepatoprotection
-
批准号:8305463
-
项目类别:
-
资助金额:$55.28万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Natural Phenotypic Diversity of HCV NS3/4A Protease
-
批准号:8309065
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Effects of Silymarin on the Metabolome
-
批准号:8634527
-
项目类别:
-
资助金额:$15.59万
-
财政年份:2011
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Mechanisms of Action of Silymarin for Hepatitis C
-
批准号:7591034
-
项目类别:
-
资助金额:$19.62万
-
财政年份:2008
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Chemokines and Acute Hepatitis C
-
批准号:8317650
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Chemokines and Acute Hepatitis C
-
批准号:8380560
-
项目类别:
-
资助金额:$22.77万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Chemokines and Acute Hepatitis C
-
批准号:7919879
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
HCV-Host Interaction during Acute Hepatitis C
-
批准号:7014420
-
项目类别:
-
资助金额:$23.26万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Chemokines and Acute Hepatitis C
-
批准号:8712327
-
项目类别:
-
资助金额:$22.52万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Chemokines and Acute Hepatitis C
-
批准号:8519233
-
项目类别:
-
资助金额:$19.7万
-
财政年份:2005
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Hepatitis C Virus Induced IL-8 & Inhibition of Interferon
-
批准号:7112467
-
项目类别:
-
资助金额:$27.45万
-
财政年份:2003
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Hepatitis C Virus Induced IL-8 & Inhibition of Interferon
-
批准号:7273696
-
项目类别:
-
资助金额:$26.66万
-
财政年份:2003
-
负责人:STEPHEN J. POLYAK
-
依托单位:
Hepatitis C Virus Induced IL-8 & Inhibition of Interferon
-
批准号:6941187
-
项目类别:
-
资助金额:$28.11万
-
财政年份:2003
-
负责人:STEPHEN J. POLYAK
-
依托单位:
海外基金